Moderna balances weaker COVID demand with cost cuts and pipeline progress

Transcript intelligence

What changed

Compared with the prior quarter, Moderna’s update put greater emphasis on the decline in COVID demand and disclosed that the CMV program had been discontinued after missing efficacy goals. At the same time, management highlighted continued cost improvement, mNEXSPIKE share gains, and progress toward flu, oncology, rare-disease and international manufacturing objectives.

Guidance delta

Management tightened 2025 revenue expectations while pointing to higher year-end cash and lower operating expenses; the stated cash-breakeven goal remains 2028.

Key takeaways

• Lower COVID demand drove a sharp revenue decline, while cost reductions limited the net loss.
• mNEXSPIKE gained the majority of Moderna’s COVID vaccination share.
• The CMV program was halted after it failed to meet efficacy goals.
• Flu, RSV, oncology and rare-disease programs remain the main pipeline catalysts.
• Manufacturing and offtake partnerships are expanding in Canada, the UK and Australia.

Management priorities

• Advance flu, RSV, oncology and rare-disease candidates toward regulatory filings or later-stage readouts.
• Continue reducing operating expenses and execute toward cash breakeven by 2028.
• Expand local manufacturing and commercial partnerships in Canada, the UK and Australia.